Mohammad Arjmand

Dr. Mohammad Arjmand

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2013 in Lasers in Medical Science
Verified
Journal Article
Closed access
PDF file
NKN. Kazemi Khoo
N. Kazemi Khoo
AIA. Iravani
A. Iravani
MAMohammad Arjmand
Mohammad Arjmand
FVF. Vahabi
F. Vahabi
MLM. Lajevardi
M. Lajevardi
ZZZahra Zamani
Zahra Zamani

27 August 2010 in Microbiology and Immunology
Verified
Journal Article
Closed access
PDF file
VYVahid Younesi
Vahid Younesi
HNHaleh Nikzamir
Haleh Nikzamir
MYMehdi Yousefi
Mehdi Yousefi
JKJalal Khoshnoodi
Jalal Khoshnoodi
MAMohammad Arjmand
Mohammad Arjmand
FSFazel Shokri
Fazel Shokri

1 January 2014 in Biochemistry Research International
Verified
Journal Article
Open access
PDF file
ZZZahra Zamani
Zahra Zamani
MAMohammad Arjmand
Mohammad Arjmand
FVFarideh Vahabi
Farideh Vahabi
SHSeyed Mahmood Eshaq Hosseini
Seyed Mahmood Eshaq Hosseini
SFSadegh Mohammad Fazeli
Sadegh Mohammad Fazeli
SKShohreh Khatami
Shohreh Khatami
Background. Colorectal carcinoma is the third cause of cancer deaths in the world. For diagnosis, invasive methods like colonoscopy and sigmoidoscopy are used, and noninvasive screening tests are not very accurate. We decided to study the potential of1HNMR spectroscopy with metabolomics and chemometrics as a preliminary noninvasive test. We obtained a distinguishing pattern of metabolites and metabolic pathways between colon cancer patient and normal.Methods. Sera were obtained from confirmed colon cancer patients and the same number of healthy controls. Samples were sent for1HNMR spectroscopy and analysis was carried out Chenomex and MATLAB software. Metabolites were identified using Human Metabolic Data Base (HDMB) and the main metabolic cycles were identified using Metaboanalyst software.Results. 15 metabolites were identified such as pyridoxine, orotidine, and taurocholic acid. Main metabolic cycles involved were the bile acid biosynthesis, vitamin B6 metabolism, methane metabolism, and glutathione metabolism.Discussion. The main detected metabolic cycles were also reported earlier in different cancers. Our observations corroborated earlier studies that suggest the importance of lowering serum LCA/DCA and increasing vitamin B6 intake to help prevent colon cancer. This work can be looked upon as a preliminary step in using1HNMR analysis as a screening test before invasive procedures.

1 June 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MSMasoud Sadeghzadeh
Masoud Sadeghzadeh
SSShahab Sheibani
Shahab Sheibani
MGMehdi Ghandi
Mehdi Ghandi
FDFariba Johari Daha
Fariba Johari Daha
MAMassoud Amanlou
Massoud Amanlou
ABAbolfazl Hasani Bozcheloie
Abolfazl Hasani Bozcheloie

1 June 2010 in Talanta
Verified
Journal Article
Closed access
MAMohammad Arjmand
Mohammad Arjmand
MKMohsen Kompany-Zareh
Mohsen Kompany-Zareh
MVMahdi Vasighi
Mahdi Vasighi
NPNastran Parvizzadeh
Nastran Parvizzadeh
ZZZahra Zamani
Zahra Zamani
FNFereshteh Nazgooei
Fereshteh Nazgooei

17 February 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MMMehdi Mohammadi
Mehdi Mohammadi
MJMahmood Jeddi-Tehrani
Mahmood Jeddi-Tehrani
FGForough Golsaz-Shirazi
Forough Golsaz-Shirazi
MAMohammad Arjmand
Mohammad Arjmand
TBTannaz Bahadori
Tannaz Bahadori
FSFazel Shokri
Fazel Shokri
Overexpression of HER2 has been reported in many types of cancer, making it a perfect candidate for targeted immunotherapy. The combination of two FDA approved monoclonal antibodies (mAbs), trastuzumab and pertuzumab, has more robust anti-tumor activity in patients with HER2-overexpressing breast cancer. We recently produced a new humanized anti-HER2 mAb, hersintuzumab, which recognizes a different epitope than trastuzumab and pertuzumab on HER2. This mAb, in combination with trastuzumab, exhibits more potent anti-tumor activity than each parental mAb alone. Here we have developed a novel bispecific anti-HER2 antibody (BsAb) designated as trasintuzumab, composed of trastuzumab and hersintuzumab, using dual variable domain immunoglobulin (DVD-Ig) technology. Both variable domains of trasintuzumab are fully functional and have similar affinities to the parental mAbs and are also able to bind to natural HER2 on the surface of several HER2-expressing cell lines. Trasintuzumab was found to inhibit the growth of different types of tumor cell lines through suppression of the AKT and ERK signaling pathways as efficiently as the combination of the parental mAbs. It also induced tumor regression as potently as the combination of the two mAbs in nude mice bearing ovarian and gastric cancer xenografts. Our data suggest that trasintuzumab may be a promising BsAb therapeutic candidate for the treatment of HER2-overexpressing cancers.